CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Choosing an index fund for retirement involves comparing Sp500 vs total market exposure, costs, and long-term growth potential.
28,502 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
In June, gold and silver prices pulled back, pressuring Hycroft Mining, a Nevada-focused, single-mine precious metals...
The SPDR S&P Semiconductor ETF jumps roughly 12% amid resilient AI-related demand, yet Intel remains a weakness in an...
Benchmark analysts cheer Strategy’s pivot to STRC as the primary funding engine for bitcoin accumulation, signaling a...
Embecta faced a sharp decline after its quarterly report, leaving investors wondering about the near-term outlook. Th...
Two AI-focused giants sit at the crossroads of growth and scale. This guide breaks down Palantir and Oracle through r...
StubHub's 2025 earnings narrative centers on the core marketplace while AI-driven product bets unfold in the backgrou...
Oil edges toward a $100 threshold as geopolitical tensions intensify. Four key energy names—Exxon, Chevron, ConocoPhi...
Klarna shares jumped about 15% intraday after a solid Q1 2026 report, fueling a debate on whether Klarna today: outpe...
The stock move is sharp, but so is the story behind choice hotels stock down. An investor dumped more than $100 milli...
Discover what the AENT 2026 earnings transcript reveals about growth, margins, and cash flow. This guide translates t...
A $10.2 billion hidden revenue stream from data-center power equipment is quietly driving the AI infrastructure boom....